Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Axial spondyloarthritis (axSpA) is an immune-mediated inflammatory disease primarily affecting the axial skeleton. The most frequent axSpA symptom is chronic, often inflammatory back pain that might be difficult to distinguish from other causes of chronic back pain. Many participants report persistent pain, including back pain, which impacts disease activity and and impairs quality of life while evoking typical disease burden such as sleep disturbance, social isolation, loss of productivity, as well as anxiety and depression. This study will assess the real-world effectiveness of upadacitinib on early and sustained disease control, and the association between pain and clinical/patient-reported outcomes in axSpA participants.
Upadacitinib is being developed for the treatment of axSpA. Approximately 352 adult participants with active axSpA will be enrolled in Germany.
Participants will receive oral upadacitinib tablets as prescribed by the physician prior to enrolling in this study in accordance with the terms of the local marketing authorization and professional and reimbursement guidelines with regards to dose, population and indication. The overall duration of the study is approximately 52 weeks.
There may be a higher burden for participants in this study compared to usual standard of care due to study procedures. Participants will attend regular visits per routine clinical practice. The effect of the treatment will be checked by medical assessments, checking for side effects, and questionnaires.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants Receiving Upadacitinib. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Upadacitinib | Drug | Tablet; Oral |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Achieving Ankylosing Spondylitis Disease Activity Score Low Disease Activity (ASDAS LDA [< 2.1]) | The ASDAS combines the following 5 disease activity variables: back pain (BASDAI Question 2 NRS score 0 - 10), peripheral pain/swelling (BASDAI Question 3 NRS score 0 - 10), duration of morning stiffness (BASDAI Question 6 NRS score 0 - 10), PtGA, and high-sensitivity c reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). Low disease is defined as an ASDAS < 2.1. | Week 24 |
| Percentage of Participants Achieving ASDAS LDA (< 2.1) (i.e., Maintenance of Response) | The ASDAS combines the following 5 disease activity variables: back pain (BASDAI Question 2 NRS score 0 - 10), peripheral pain/swelling (BASDAI Question 3 NRS score 0 - 10), duration of morning stiffness (BASDAI Question 6 NRS score 0 - 10), PtGA, and high-sensitivity c reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). Low disease is defined as an ASDAS < 2.1. Maintenance of response is defined as those achieving LDA at Week 24 and Week 52. | Up to Week 52 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Achieving Assessment of Spondyloarthritis International Society Health Index (ASAS-HI) Score of 40 | The ASAS-HI has been developed to measure functioning and health in participants with SpA with the aim of defining and comparing the impact of the disease and health based on the biopsychosocial model of disease proposed by the International Classification of Functioning, Disability and Health (ICF). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult participants with axial spondylarthritis (axSpA) who have been prescribed upadacitinib in the course of routine practice according to relevant approved licenses.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| ABBVIE INC. | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| ACURA Rheumazentrum Baden-Bade /ID# 249751 | Baden-Baden | Baden-Wurttemberg | 76530 | Germany | ||
| Heilig, Heidelberg, DE /ID# 240492 |
Not provided
| Label | URL |
|---|---|
| This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Up to Week 52 |
| Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score < 4 | The BASDAI is a commonly used measure to define disease activity levels in axSpA participants. The overall BASDAI score ranges from 0 to 10, with higher scores indicating greater disease activity. | Up to Week 52 |
| Percentage of Participants Achieving ASDAS Inactive Disease (ID [< 1.3]) | The ASDAS combines the following 5 disease activity variables: back pain (BASDAI Question 2 NRS score 0 - 10), peripheral pain/swelling (BASDAI Question 3 NRS score 0 - 10), duration of morning stiffness (BASDAI Question 6 NRS score 0 - 10), PtGA, and high-sensitivity c reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). Inactive disease is defined as an ASDAS < 1.3. | Up to Week 52 |
| Percentage of Participants Achieving ASDAS LDA (< 2.1) | The ASDAS is a composite index with proven validity and reliability to assess disease activity in axSpA participants, with LDA defined as a score < 2.1. | Up to Week 52 |
| Change from Baseline in BASDAI | The BASDAI is a commonly used measure to define disease activity levels in axSpA participants. The overall BASDAI score ranges from 0 to 10, with higher scores indicating greater disease activity. | Up to Week 52 |
| Change from Baseline in BASDAI at Week 1-4 | The BASDAI is a commonly used measure to define disease activity levels in axSpA participants. The overall BASDAI score ranges from 0 to 10, with higher scores indicating greater disease activity. | Week 4 |
| Percentage of Participants with Resolution of Enthesitis (Leeds Enthesitis Index [LEI] = 0) for Participants with Baseline Enthesitis | The LEI is a clinical index used to assess enthesitis. It consists of 3 bilateral sites: Achilles tendon insertions, medial femoral condyles, and lateral epicondyles of the humerus. Tenderness at each site is quantified on a dichotomous basis: 0 means nontender and 1 means tender. | Up to Week 52 |
| Percentage of Participants with Resolution of Dactylitis for Participants with Baseline Dactylitis | Presence of dactylitis (Yes/No) will be assessed by the physician. | Up to Week 52 |
| Mean Change from Baseline in ASAS-HI | The ASAS-HI has been developed to measure functioning and health in patients with SpA with the aim of defining and comparing the impact of the disease and health based on the biopsychosocial model of disease proposed by the ICF. | Up to Week 52 |
| Percentage of Participants with ASAS-HI <= 4 | The ASAS-HI has been developed to measure functioning and health in patients with SpA with the aim of defining and comparing the impact of the disease and health based on the biopsychosocial model of disease proposed by the ICF. | Up to Week 52 |
| Mean Change from Baseline in Nocturnal Back Pain in Past 24 Hours | Pain will be measured using a 0 - 10 numerical rating scale (NRS) for nocturnal back pain (0 = no pain and 10 = most severe pain). | Up to Week 52 |
| Mean Change from Baseline in Total Back Pain in Past 24 Hours | Pain will be measured using a 0 - 10 numerical rating scale (NRS) for nocturnal back pain (0 = no pain and 10 = most severe pain). | Up to Week 52 |
| Mean Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) | The BASFI is a validated PRO instrument for use in the axSpA participant population. It consists of 10 items measured on a 0 to 10 NRS, which assesses the ability to perform activities known to be problematic to axSpA participants such as dressing, bending, reaching, turning, and climbing steps. The total scores range from 0 to 10 with higher scores indicating worse physical functioning in axSpA participants. | Up to Week 52 |
| Mean Change from Baseline in Patient Health Questionnaire-4 (PHQ-4) | The 4-item PHQ-4 is an ultra-brief self-report questionnaire that consists of a 2-item depression scale (PHQ-2) and a 2-item anxiety scale (GAD-2). It is rated on a 4-point Likert-type scale. Its purpose is to allow for very brief and accurate measurement of depression and anxiety. | Up to Week 52 |
| Percentage of Participants with Recurrence of Typical Extra-Musculoskeletal Manifestations (EMMs) | Participants with recurrence of typical extra-musculoskeletal manifestations (EMMs. | Up to Week 52 |
| Percentage of Participants with new onset of typical EMMs | Participants with new onset of typical EMMs | Up to Week 52 |
| Heidelberg |
| Baden-Wurttemberg |
| 69120 |
| Germany |
| Rheumatologische Schwerpunktpraxis /ID# 245392 | Stuttgart | Baden-Wurttemberg | 70372 | Germany |
| Praxis Dr. Haas /ID# 242982 | Tübingen | Baden-Wurttemberg | 72072 | Germany |
| Praxis Dr. Rinaldi /ID# 242984 | Ulm | Baden-Wurttemberg | 89073 | Germany |
| Praxis K. Pagel /ID# 240490 | Hoppegarten | Brandenburg | 15366 | Germany |
| Rheumahaus Studien GbR, Potsdam, DE /ID# 245231 | Potsdam | Brandenburg | 14467 | Germany |
| Praxis Dr. Sabine Reckert /ID# 245142 | Potsdam | Brandenburg | 14469 | Germany |
| Fachpraxis fuer Rheumatologie und Osteologie /ID# 243358 | Bruchhausen-Vilsen | Lower Saxony | 27305 | Germany |
| Stille, Hanover, DE /ID# 252222 | Hanover | Lower Saxony | 30161 | Germany |
| Praxis. F. Bigdeli-Wilshusen /ID# 272904 | Hanover | Lower Saxony | 30173 | Germany |
| Medizinische Hochschule Hannover /ID# 262814 | Hanover | Lower Saxony | 30625 | Germany |
| Rheumatologie Kassel /ID# 275998 | Kassel | Lower Saxony | 34125 | Germany |
| Krankenhaus Porz am Rhein /ID# 243765 | Cologne | North Rhine-Westphalia | 51149 | Germany |
| Rheumazentrum Ruhrgebiet /ID# 240460 | Herne | North Rhine-Westphalia | 44649 | Germany |
| Beyer, Kaiserslautern, DE /ID# 240444 | Kaiserslautern | Rhineland-Palatinate | 67659 | Germany |
| Krankenhaus der Barmherzigen Brüder Trier /ID# 240524 | Trier | Rhineland-Palatinate | 54292 | Germany |
| Praxis Bernd Mueller /ID# 240488 | Homburg | Saarland | 66424 | Germany |
| Rheumapraxis Dr. Prothmann /ID# 240671 | Püttlingen | Saarland | 66346 | Germany |
| Medizinischen Versorgungszentrums Agilomed /ID# 240481 | Chemnitz | Saxony | 09130 | Germany |
| Rheumatologisches Medizinisches Versorgungszentrum Dresden /ID# 240516 | Dresden | Saxony | 01109 | Germany |
| Hamann and Teich and Boche,Leipzig /ID# 240445 | Leipzig | Saxony | 04109 | Germany |
| Praxis internistische Rheumatologie /ID# 240515 | Leipzig | Saxony | 04129 | Germany |
| Praxis Dr. Liebhaber /ID# 240480 | Halle | Saxony-Anhalt | 06128 | Germany |
| Aurich and Sieburg, Magdeburg /ID# 240518 | Magdeburg | Saxony-Anhalt | 39104 | Germany |
| Rheumatologische Facharztpraxis - Naumburg (Saale) /ID# 240477 | Naumburg | Saxony-Anhalt | 06618 | Germany |
| Rheumatologische Praxis Dr. Jochen Walter /ID# 250263 | Rendsburg | Schleswig-Holstein | 24768 | Germany |
| Kupka and Kupka, Altenburg, DE /ID# 240479 | Altenburg | Thuringia | 04600 | Germany |
| MVZ Ambulantes Rheumazentrum Erfurt /ID# 244448 | Erfurt | Thuringia | 99096 | Germany |
| Rheumapraxis Weimar /ID# 268387 | Weimar | Thuringia | 99427 | Germany |
| Marycz, Amberg, DE /ID# 240483 | Amberg | 92224 | Germany |
| Rheumapraxis am Webereck /ID# 240454 | Augsburg | 86157 | Germany |
| Praxis S. Bresgulewski /ID# 240662 | Bad Bertrich | 56864 | Germany |
| Kerckhoff Klinik /ID# 252219 | Bad Nauheim | 61231 | Germany |
| Rheumapraxis Berlin /ID# 242987 | Berlin | 12435 | Germany |
| Praxis Dr. med. Angela Seifert /ID# 245107 | Berlin | 12555 | Germany |
| Praxis Dr. Silke Zinke /ID# 240526 | Berlin | 13055 | Germany |
| Krankenhaus Waldfriede /ID# 268389 | Berlin | 14163 | Germany |
| Eisterhues, Braunschweig, DE /ID# 239438 | Braunschweig | 38100 | Germany |
| MVZ Herzogin Elisabeth Hospital /ID# 267983 | Braunschweig | 38114 | Germany |
| Dr. Walberer /ID# 249752 | Burglengenfeld | 93133 | Germany |
| Private Practice - Dr. Sebastian Schuh /ID# 240498 | Coburg | 96450 | Germany |
| Dres. Karger/Baerlecken /ID# 240442 | Cologne | 50996 | Germany |
| MVZ-Medizinisches Versorgungszentrum Daun GmbH /ID# 254839 | Daun | 54550 | Germany |
| Kreiskrankenhaus Demmin /ID# 240451 | Demmin | 17109 | Germany |
| Praxis Dilltal /ID# 240520 | Ehringshausen | 35630 | Germany |
| Private Practice - Dr. Daniel Bestler /ID# 251860 | Erfurt | 99096 | Germany |
| Michael Mueller, Freiberg, DE /ID# 240489 | Freiberg | 09599 | Germany |
| Praxis Dres. Sensse/Sensse /ID# 240517 | Gifhorn | 38518 | Germany |
| Private Practice - Dr. Hauke E. Heintz /ID# 254037 | Hamburg | 22391 | Germany |
| Dres. Weinhardt/Knobel/Doepfer /ID# 248195 | Hamburg | 22523 | Germany |
| Zentrum fuer Rheumatologie und Schmerzmedizin /ID# 244370 | Hanover | 30159 | Germany |
| Wernicke, Hohen Neuendorf, DE /ID# 250626 | Hohen Neuendorf | 16540 | Germany |
| Kremers, Juelich, DE /ID# 243357 | Jülich | 52428 | Germany |
| Dr. Bolze, Ludwigshafen, DE /ID# 251012 | Ludwigshafen | 67069 | Germany |
| Praxis Dr. Annekatrin Rossbach /ID# 240495 | Mansfeld / Großörner | 06343 | Germany |
| Harmuth, Marktredwitz, DE /ID# 240455 | Marktredwitz | 95615 | Germany |
| RHIO Forschungsinstitut /ID# 240525 | Meerbusch | 40668 | Germany |
| Prof-med-stud.de /ID# 240458 | Munich | 80935 | Germany |
| Praxis Dr. med Thilo Klopsch /ID# 240461 | Neubrandenburg | 17033 | Germany |
| Praxis Hein & Gess /ID# 240456 | Nienburg | 31582 | Germany |
| MVZ für Rheumatologie Dr. M. Welcker /ID# 240521 | Planegg | 82152 | Germany |
| Baumann & Lang, Plauen, DE /ID# 244369 | Plauen | 08523 | Germany |
| Rheumazentrum Ratingen /ID# 240465 | Ratingen | 40882 | Germany |
| Melzer, Seesen, DE /ID# 240484 | Seesen | 38723 | Germany |
| Barmherzige Bruder MVZ Klinikum Straubing GmbH /ID# 240523 | Straubing | 94315 | Germany |
| Rheumathologie Ulm /ID# 240494 | Ulm | 89073 | Germany |
| Praxis F. Schattenberg /ID# 257646 | Waren | 17192 | Germany |
| Krankenhaus St. Josef /ID# 249747 | Wuppertal | 42105 | Germany |
| Praxis Barmen /ID# 240449 | Wuppertal | 42285 | Germany |
| Praxis Barmen /ID# 277515 | Wuppertal | 42285 | Germany |
| Fricke-Wagner, Zwickau, DE /ID# 240452 | Zwickau | 08060 | Germany |
| ID | Term |
|---|---|
| C000613732 | upadacitinib |
Not provided
Not provided
Not provided